{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-001836","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.541841+00:00","generated_at":"2026-06-19T23:55:31.467413+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"aTyr Pharma's partner Kyorin doses first patient in Phase 3 EFZO-FIT study; receives $10M milestone","bullets":["Kyorin dosed first patient in Japan in global pivotal Phase 3 EFZO-FIT trial of efzofitimod for pulmonary sarcoidosis.","Milestone payment of $10M triggered under Kyorin agreement; total upfront and milestones to date $20M.","aTyr eligible for up to $155M additional development, regulatory, and sales milestones plus royalties on Japan net sales.","Kyorin holds exclusive rights to develop and commercialize efzofitimod for all interstitial lung diseases in Japan."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-001836","json":"https://secwatch.observer/filing/0000950170-23-001836.json","markdown":"https://secwatch.observer/filing/0000950170-23-001836.md","text":"https://secwatch.observer/filing/0000950170-23-001836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023001836/0000950170-23-001836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023001836/life-20230206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T23:55:31.467413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}